US2021395189A1PendingUtilityA1

Substituted tetracycline compounds

Assignee: PARATEK PHARM INNCPriority: Dec 21, 2006Filed: Jan 4, 2021Published: Dec 23, 2021
Est. expiryDec 21, 2026(~0.4 yrs left)· nominal 20-yr term from priority
C07D 263/32C07D 261/02C07D 307/52C07D 231/12C07D 265/02C07D 207/20C07D 295/13C07D 207/50A61P 17/02C07C 2603/46A61P 31/12C07D 239/26C07D 261/04C07C 237/26C07D 239/20A61K 31/65A61P 33/14A61P 29/00C07D 265/30A61P 33/00A61P 25/28C07D 211/14A61P 11/02C07D 241/12A61P 31/04A61P 33/06A61P 17/10A61P 31/00A61P 17/00A61P 25/00Y02A50/30
69
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms.

Claims

exact text as granted — not AI-modified
1 - 391 . (canceled) 
     
     
         392 . A method for treating a tetracycline responsive state in a subject, comprising administering to said subject an effective amount of a tetracycline compound of formula (VIIA): 
       
         
           
           
               
               
           
         
         wherein:
 X is CR 6 *CR 6*′ ; 
 R 5*′  is hydrogen; 
 R 5*′  is hydrogen or hydroxyl; 
 R 6*′  is hydrogen or alkyl; 
 R 6*′  is hydrogen; 
 R 7′  is alkylamino; and 
 R 9m*  is oxazolyl or isoxazolyl or a pharmaceutically acceptable salt thereof, such that said subject is treated.

Join the waitlist — get patent alerts

Track US2021395189A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.